

Quentin M Anstee, Frcp

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6949623/quentin-m-anstee-frcp-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

214 papers	18,496 citations	63 h-index	134 g-index
280 ext. papers	26,869 ext. citations	7.4 avg, IF	7.15 L-index

#	Paper	IF	Citations
214	Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	1
213	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. <i>Journal of Hepatology</i> , 2022 ,	13.4	5
212	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022 , 5, 61-90	0.3	0
211	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
210	Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.. <i>JHEP Reports</i> , 2022 , 4, 100411	10.3	3
209	Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.. <i>BMJ Open</i> , 2022 , 12, e049767	3	2
208	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.. <i>BMJ Open</i> , 2022 , 12, e056159	3	1
207	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. <i>Hepatology</i> , 2022 ,	11.2	2
206	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2
205	Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.. <i>Hepatology Communications</i> , 2022 ,	6	2
204	Clinicians' Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2707	5.1	
203	Impact of non-invasive biomarkers on hepatology practice: Past, present and future.. <i>Journal of Hepatology</i> , 2022 , 76, 1362-1378	13.4	1
202	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
201	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
200	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 ,	13.3	5
199	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021 , 13, eabe8939	17.5	3
198	Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. <i>American Journal of the Medical Sciences</i> , 2021 ,	2.2	

197	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
196	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
195	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021 ,	11.2	7
194	Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study. <i>Patient</i> , 2021 , 14, 533-543	3.7	9
193	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 185-198	18.8	36
192	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
191	A Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021 , 13,	6.6	5
190	Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial. <i>BMJ Open</i> , 2021 , 11, e045922	3	78
189	NAFLD-Associated HCC: Progress and Opportunities. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 223-239	3.9	11
188	European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021 , 3, 100234	10.3	13
187	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
186	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021 , 74, 133-147	11.2	20
185	Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
184	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 717-729	24.2	16
183	Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2021 , 8,	3.9	2
182	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
181	Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma. <i>Hepatology</i> , 2021 , 73, 1028-1044	11.4	22
180	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50

179	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 , 160, 1608-1619.e13	13.3	15
178	Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. <i>Liver International</i> , 2021 , 41, 261-270	7.9	29
177	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021 , 74, 20-30	13.4	24
176	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2021 ,	19.2	27
175	The pathway to better primary care for chronic liver disease. <i>British Journal of General Practice</i> , 2021 , 71, 180-182	1.6	0
174	A molecular signature for the metabolic syndrome by urine metabolomics. <i>Cardiovascular Diabetology</i> , 2021 , 20, 155	8.7	4
173	Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. <i>Hepatology</i> , 2021 , 74, 2452-2466	11.2	15
172	Embedding assessment of liver fibrosis into routine diabetic review in primary care. <i>JHEP Reports</i> , 2021 , 3, 100293	10.3	3
171	Key features of the environment promoting liver cancer in the absence of cirrhosis. <i>Scientific Reports</i> , 2021 , 11, 16727	4.9	4
170	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1253-1266	4.2	3
169	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 835-856	24.2	27
168	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
167	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 786-794	13.4	21
166	Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. <i>Journal of Medical Internet Research</i> , 2021 , 23, e20491	7.6	1
165	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
164	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.. <i>Biomedicines</i> , 2021 , 9,	4.8	4
163	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. <i>Gastroenterology</i> , 2020 , 159, 534-548.e11	13.3	29
162	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020 , 2, 514-531	14.6	17

161	Selonertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020 , 73, 26-39	13.4	137
160	Reply. <i>Hepatology</i> , 2020 , 72, 786	11.2	
159	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
158	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 362-373	18.8	151
157	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020 , 158, 1611-1625.e12	13.3	234
156	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. <i>PLoS Medicine</i> , 2020 , 17, e1003100	11.6	66
155	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020 , 73, 252-262	13.4	65
154	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
153	Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. <i>JHEP Reports</i> , 2020 , 2, 100099	10.3	10
152	Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2020 , 73, 221-222	13.4	1
151	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020 , 88, 105889	2.3	45
150	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020 , 71, 1953-1966	11.2	27
149	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020 , 89, 105922	2.3	49
148	Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00231	4.2	14
147	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
146	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
145	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 970-985	18.8	54
144	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020 , 2, 100143	14.3	20

143	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1289-1292	0.7	5
142	Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2020 , 73, 1582-1583	13.4	
141	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020 , 4, 1637-1650	6	12
140	Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020 , 15, e0238717	3.7	14
139	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020 , 72, 14-24	13.4	75
138	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. <i>Translational Behavioral Medicine</i> , 2020 , 10, 1016-1030	3.2	14
137	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
136	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies 2020 , 17, e1003100		
135	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies 2020 , 17, e1003100		
134	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies 2020 , 17, e1003100		
133	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies 2020 , 17, e1003100		
132	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019 , 1, 188-198	10.3	46
131	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019 , 70, e5	13.4	33
130	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2552-2560.e10	6.9	33
129	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019 , 70, 1841-1855	11.2	41
128	From NASH to HCC: current concepts and future challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 411-428	24.2	425
127	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019 , 156, 1717-1730	13.3	356
126	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2085-2092.e1	6.9	41

125	The degree of hepatic steatosis associates with impaired cardiac and autonomic function. <i>Journal of Hepatology</i> , 2019 , 70, 1203-1213	13.4	26
124	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. <i>Hepatology</i> , 2019 , 70, 1424-1436	11.2	44
123	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. <i>Journal of Hepatology</i> , 2019 , 71, 823-833	13.4	64
122	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019 , 84, 105803	2.3	72
121	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019 , 70, 1521-1530	11.2	113
120	2942 Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design. <i>American Journal of Gastroenterology</i> , 2019 , 114, S1601-S1602	0.7	1
119	Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1364-1371.e3	6.9	19
118	OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH 2019 ,		5
117	938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>American Journal of Gastroenterology</i> , 2019 , 114, S546-S546	0.7	
116	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	4.0	425
115	Central obesity and nonalcoholic fatty liver disease in people living with HIV: a case for targeted screening?. <i>HIV Medicine</i> , 2019 , 20, e1-e2	2.7	3
114	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 425-439	24.2	114
113	Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. <i>Clinical Medicine</i> , 2018 , 18, s54-s59	1.9	14
112	Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. <i>Hepatology Research</i> , 2018 , 48, 69-77.	5.1	22
111	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018 , 67, 2001-2012	11.2	79
110	Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. <i>Hepatology</i> , 2018 , 67, 1270-1283	11.2	225
109	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 11-20	24.2	1902
108	Fatty Liver Disease 2018 , 308-371		6

107	Thrombin and factor Xa link the coagulation system with liver fibrosis. <i>BMC Gastroenterology</i> , 2018 , 18, 60	3	24
106	Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants. <i>BMC Biology</i> , 2018 , 16, 70	7.3	50
105	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
104	The EPOs staging system is a reproducible 7-tier fibrosis score for NAFLD adapted both to glass slides and digitized images (e-slides). <i>Journal of Hepatology</i> , 2018 , 68, S553	13.4	6
103	Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease 2018 , 391-405.e3		1
102	The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. <i>Journal of Hepatology</i> , 2018 , 68, 251-267	13.4	75
101	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. <i>Contemporary Clinical Trials</i> , 2018 , 75, 67-71	2.3	10
100	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1109-1116	6.1	53
99	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018 , 69, 878-885	13.4	75
98	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis 2018 , 68, 349		1
97	Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. <i>Journal of Hepatology</i> , 2017 , 67, 128-136	13.4	70
96	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. <i>Gut</i> , 2017 , 66, 1321-1328	19.2	128
95	Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1596-1603.e3	6.9	5
94	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , 2017 , 8, 252-259	2.6	15
93	Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1968-1971	6.9	17
92	Cellular senescence drives age-dependent hepatic steatosis. <i>Nature Communications</i> , 2017 , 8, 15691	17.4	408
91	NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 506-507	24.2	19
90	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. <i>Gut</i> , 2017 , 66, 1138-1153	19.2	508

89	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
88	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , 2017 , 66, S593	13.4	7
87	Exploring the patient perceived impact of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2017 , 66, S422-S423	13.4	2
86	The PDGFR α -laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. <i>Oncogene</i> , 2017 , 36, 6605-6616	9.2	31
85	Genetic variation in GABRA1 and the risk for developing alcohol dependence. <i>Psychiatric Genetics</i> , 2017 , 27, 110-115	2.9	5
84	Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. <i>Nature</i> , 2017 , 551, 340-345	50.4	224
83	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , 2017 , 60, 1873-1882	10.3	51
82	Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. <i>Journal of Hepatology</i> , 2017 , 66, S110-S111	13.4	3
81	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
80	Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 96-102.e3	6.9	92
79	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
78	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017 , 12, e0175717	3.7	35
77	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 877-89	6.1	54
76	How to Diagnose Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , 2016 , 34 Suppl 1, 19-26	3.2	11
75	Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016 , 150, 1728-1744.e7	13.3	133
74	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016 , 150, 1147-1159.e5	13.3	629
73	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. <i>Aging</i> , 2016 , 9, 26-40	5.6	7
72	Non-alcoholic Fatty Liver Disease (NAFLD) and Bariatric Surgery 2016 , 629-636		1

71 Can genetic influence in non-alcoholic fatty liver disease be ignored? **2016**, 91-102

70 Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. *Annual Review of Pathology: Mechanisms of Disease*, **2016**, 11, 451-96 34 296

69 Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 1109-23 6.1 31

68 Non-alcoholic fatty liver disease is associated with higher levels of measured sedentary behaviour and lower levels of physical activity than matched healthy controls. *Frontline Gastroenterology*, **2015**, 6, 44-51 2.6 65

67 TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?. *Gastroenterology*, **2015**, 148, 679-84 13.3 58

66 Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. *Clinical Epigenetics*, **2015**, 7, 25 7.7 104

65 Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. *Journal of Hepatology*, **2015**, 62, 1148-55 13.4 626

64 Foreword. Nonalcoholic Fatty Liver Disease. *Seminars in Liver Disease*, **2015**, 35, 203-6 7.3 4

63 The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. *Seminars in Liver Disease*, **2015**, 35, 270-90 7.3 106

62 The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. *Liver International*, **2015**, 35, 764-73 7.9 36

61 Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. *Journal of Hepatology*, **2015**, 62, 982-3 13.4 13

60 Genetics of Alcoholic Liver Disease. *Seminars in Liver Disease*, **2015**, 35, 361-74 7.3 29

59 Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. *Clinical Science*, **2015**, 129, 1097-105 6.5 113

58 An overview of the genetics, mechanisms and management of NAFLD and ALD. *Clinical Medicine*, **2015**, 15 Suppl 6, s77-82 1.9 13

57 Nonalcoholic fatty liver disease: new treatments. *Current Opinion in Gastroenterology*, **2015**, 31, 175-83 3 65

56 TM6SF2 as a genetic risk factor for fibrosis. *Hepatology*, **2015**, 62, 1321 11.2 2

55 Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. *Postgraduate Medical Journal*, **2015**, 91, 92-101 2 14

54 Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. *Journal of Clinical Investigation*, **2015**, 125, 501-20 15.9 130

53	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Postgraduate Medical Journal</i> , 2014 , 90, 254-66	2	7
52	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
51	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area". <i>Journal of Hepatology</i> , 2014 , 60, 1330-1	13.4	1
50	Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 61, 75-81	13.4	310
49	Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. <i>Clinical and Translational Gastroenterology</i> , 2014 , 5, e56	4.2	33
48	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. <i>Cell Cycle</i> , 2014 , 13, 1489-94	4.7	44
47	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. <i>Frontline Gastroenterology</i> , 2014 , 5, 211-218	2.6	168
46	Prophylaxis of bacterial infections in cirrhosis: is an optimal 25-OH vitamin D level required?. <i>Journal of Hepatology</i> , 2014 , 61, 965-6	13.4	4
45	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014 , 60, 1055-62	13.4	57
44	Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition. <i>Nature Communications</i> , 2013 , 4, 2816	17.4	37
43	Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2013 , 58, 757-62	13.4	99
42	1275 CARRIAGE OF PNPLA3 I148M IS ASSOCIATED WITH AN INCREASED RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE ASSOCIATED HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2013 , 58, S516	13.4	6
41	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013 , 58, S46	13.4	6
40	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 330-44	24.2	1022
39	Genetic Predisposition to NAFLD and NASH: Implications for Pathogenesis, Diagnosis, Prevention, and Management 2013 , 157-170		
38	The genetics of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 645-55	24.2	232
37	Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. <i>Frontline Gastroenterology</i> , 2013 , 4, 263-269	2.6	15
36	Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 652-8	2.2	57

35	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5219-38	3.3	148
34	Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. <i>PLoS ONE</i> , 2013 , 8, e61870	3.7	31
33	81 A ROLE FOR ANTICOAGULATION IN FIBROGENESIS: SUPPRESSION OF HUMAN HEPATIC STELLATE CELL CONTRACTILITY AND LIVER FIBROSIS IN VITRO AND VIVO. <i>Journal of Hepatology</i> , 2012 , 56, S35-S36	13.4	3
32	Multigenerational epigenetic adaptation of the hepatic wound-healing response. <i>Nature Medicine</i> , 2012 , 18, 1369-77	50.5	217
31	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. <i>Journal of Hepatology</i> , 2012 , 56, 448-54	13.4	126
30	A lipid to treat non-alcoholic fatty liver disease - the dawn of 'lipo-rehabilitation'?. <i>Journal of Hepatology</i> , 2012 , 56, 987-9	13.4	5
29	S-adenosylmethionine (SAME) therapy in liver disease: a review of current evidence and clinical utility. <i>Journal of Hepatology</i> , 2012 , 57, 1097-109	13.4	150
28	Quantifying hepatic steatosis - more than meets the eye. <i>Histopathology</i> , 2012 , 60, 971-81	7.3	54
27	The role of hypercoagulability in liver fibrogenesis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 526-33	2.4	64
26	Genetic modifiers of non-alcoholic fatty liver disease progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011 , 1812, 1557-66	6.9	54
25	Hypercoagulability in cirrhosis: causes and consequences. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 1713-23	15.4	182
24	Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. <i>Liver International</i> , 2011 , 31, 440-2	7.9	22
23	Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. <i>Lasers in Surgery and Medicine</i> , 2011 , 43, 392-400	3.6	10
22	How big a problem is non-alcoholic fatty liver disease?. <i>BMJ, The</i> , 2011 , 343, d3897	5.9	129
21	Genetics of alcoholic and nonalcoholic fatty liver disease. <i>Seminars in Liver Disease</i> , 2011 , 31, 128-46	7.3	91
20	Investigating mildly abnormal serum aminotransferase values. <i>BMJ, The</i> , 2010 , 341, c4039	5.9	18
19	Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2010 , 53, 542-50	13.4	122
18	The importance of fatty liver disease in clinical practice. <i>Proceedings of the Nutrition Society</i> , 2010 , 69, 518-27	2.9	13

17	The International Normalized Ratio (INR) in the MELD score: problems and solutions. <i>American Journal of Transplantation</i> , 2010 , 10, 1349-53	8.7	59
16	Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. <i>Hepatology</i> , 2010 , 51, 1859; author reply 1859-60	11.2	12
15	A missense mutation in the non-neural G-protein alpha-subunit isoforms modulates susceptibility to obesity. <i>International Journal of Obesity</i> , 2009 , 33, 507-18	5.5	20
14	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. <i>Clinical Science</i> , 2009 , 116, 403-13	6.5	29
13	Parenchymal extinction: coagulation and hepatic fibrogenesis. <i>Clinics in Liver Disease</i> , 2009 , 13, 117-126	4.6	67
12	Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1336-43	15.4	89
11	Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 1403-9	4	25
10	Hypercoagulation and thrombophilia in liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 2-9	15.4	120
9	Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. <i>International Journal of Experimental Pathology</i> , 2006 , 87, 1-16	2.8	527
8	The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2000 , 12, 1089-93	2.2	16
7	Vectorial function of major histocompatibility complex class II in a human intestinal cell line. <i>Immunology</i> , 1999 , 98, 16-26	7.8	6
6	Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways		1
5	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1
4	New Challenges of the NAFLD and HIV Epidemics35-41		
3	A trans-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation		5
2	Hepatitis B and Hepatitis C Co-Infection192-195		
1	A multi-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> ,	36.3	2